Stocktoria
Elicio Therapeutics, Inc. ELTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-02-05
Elicio Therapeutics, Inc. statistics & valuation
Market cap$76.3M
P / B46.7×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | — | — | -1031.4% | -138.8% |
| Net margin | — | — | — | -1225.9% | -192.8% |
| FCF margin | — | — | — | -992.3% | -187.3% |
| Return on assets | -153.0% | -184.2% | -129.7% | -124.5% | -56.5% |
| Return on equity | -2418.8% | 458.8% | -309.5% | 27.6% | 73.2% |
| Debt / equity | 6.11× | -1.77× | — | — | -0.00× |
| Current ratio | 2.38 | 1.80 | 1.68 | 1.56 | 8.08 |
| Revenue growth | — | — | — | -91.9% | 883.1% |
Source: SEC EDGAR filings · CIK 0001601485 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.